Biote (BTMD) Stock Price

Biote Price

OTC·CLOSED
1.09
​
Market closed

Over the last 6 years Biote grew revenue by 9.8% annually, reaching 192.22 M USD. Earnings per share have grown at 2.8% per year over the last 6 years. For Biote, the net margin of 14.1% is down versus 23.4% a few years ago.

Biote stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biote business model & stock analysis

biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas and currently employs 186 full-time employees. The company went IPO on 2021-03-02. The firm provides the necessary components to enable Biote-certified practitioners to establish, build, and implement a program designed to optimize hormone levels. The firm's Biote Method is a comprehensive, end-to-end practice-building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The company also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) assists physicians in establishing individualized dosing for patients.

Frequently asked questions about Biote

11 analysts currently rate the Biote stock: 9 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Biote to generate revenue of 178.00 M USD and earnings per share of 0.04 USD.

Converted at the current exchange rate, the Biote share trades at 0.97 EUR (1.09 USD).

The expected revenue of Biote is 178.00 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Biote is 1.26 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Biote is currently 26.76. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biote stock.

The price-to-sales ratio (P/S) of Biote is currently 0.19. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biote stock.

The Eulerpool Quality Score for Biote is 4/10.

The ISIN of Biote is US0906831039. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Biote is BTMD. The ticker symbol is used to trade Biote shares on the stock exchange.

Fair ValueTerminal
0.94 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
1.03 M USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Mar 2, 2021
ISIN
US0906831039
Cusip
090683103
Market capitalization
49.77 M USDMicro Cap
52-Week Range
PEG
0.02
P/E ratio
P/Ee 2026
39.64
P/Ee 2027
4.59
P/Ee 2028
2.18
P/Ee 2029
2.06
P/Ee 2030
1.95
P/S
P/Se
0.19
EV/EBIT
2.91
P/B Ratio
12.07
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
52.63 %
Last updated Oct 22, 2026, 12:22 AM

Biote Peer Group

Biote Ticker

OTC · BTMD

Biote FIGI

BTMD:US · BBG00ZCMCB75BTMD:UA · BBG00ZCMCB84BTMD:UC · BBG00ZCMCB93BTMD:UN · BBG00ZCMCBC9BTMD:UP · BBG00ZCMCBD8BTMD:UQ · BBG00ZCMCBF6BTMD:UB · BBG00ZCMCBG5BTMD:UM · BBG00ZCMCBJ2BTMD:UX · BBG00ZCMCBK0BTMD:UD · BBG00ZCMCBR3BTMD:UF · BBG00ZCMCBV8BTMD:VY · BBG00ZCMCBW7

All fundamentals and in-depth analysis of Biote

Our stock analysis for Biote stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biote. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.